Nadofaragene Firadenovec

gene therapy

Identifier: CI-DRUG-00000774
Entity page: /drug/nadofaragene-firadenovec ↗
Edges: 19

Neighbours: 7 cancers1 genes10 trials1 approvals
Drawn: 19 of 19 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Nadofaragene Firadenovec approved for …APPROVED_FOR2 of 1
→ approved for	Non-Muscle Invasive Bladder Carcinomasubtype	supports	EMA indication text	Non-Muscle Invasive Bladder Carcinoma	1	Regulatory	ema	graph →
→ approved for	Health Canada · CAMarketed in Canada as ADSTILADRIN (DIN 02566680) under ATC L01XL10 NADOFARAGENE FIRADENOVEC. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Nadofaragene Firadenovec targets …TARGETS1 of 1
→ targets	IFNA2	—	EXOGENOUS GENE	—	1	Curated	chembl	graph →

Nadofaragene Firadenovec targets …TARGETS1 of 1

→ targets

IFNA2

—

EXOGENOUS GENE

—

Curated

Nadofaragene Firadenovec investigated for …INVESTIGATED_FOR2 of 2
→ investigated for	Bladder Neoplasmsubtype	unknown	3	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Malignant Mesotheliomacancer_family	unknown	3	Malignant Mesothelioma	1	Curated	chembl	graph →

Nadofaragene Firadenovec investigated in trials for …INVESTIGATED_IN_TRIALSderived5 of 5
→ investigated in trials for	Malignant Bladder Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Muscle Invasive Bladder Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Muscle Invasive Bladder Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma In Situ 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Muscle Invasive Bladder Urothelial Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pleural Malignant Mesothelioma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pleural Malignant Mesothelioma	1	Observed	clinicaltrials	graph →

Nadofaragene Firadenovec studied in …STUDIED_INderived10 of 10
→ studied in	NCT06510374Phase 3 · recruiting Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer · 10 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06545955Phase 3 · recruiting A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer · 10 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07332351Phase 2 · not yet recruiting Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · 10 trials list this drug (5 active)	—	—	Malignant Bladder Neoplasm,Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06668493Phase 1/Phase 2 · recruiting Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis · 10 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06929286Phase 3 · recruiting A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) · 10 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03710876Phase 3 · completed Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma · 10 trials list this drug (5 active)	—	—	Pleural Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06026332terminated ADSTILADRIN Early Utilization and Outcomes in the Real World Setting · 10 trials list this drug (5 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06390111Phase 4 · withdrawn A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. · 10 trials list this drug (5 active)	—	—	Carcinoma In Situ,Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02773849Phase 3 · completed ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) · 10 trials list this drug (5 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01687244Phase 2 · completed Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer · 10 trials list this drug (5 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths